Dr Jaume Mora told the European Cancer Conference (ECCO 14) in Barcelona today (Tuesday) that this was the first time that such a response had been achieved in children with high grade gliomas, while in low grade gliomas the response was comparable with the best achieved by other chemotherapies. All six children were still alive at one year, although the disease had progressed in three children with the most life-threatening tumours. The usual average survival rate for BSGs is between 4-15 months.
Dr Mora, who is head of the department of paediatric oncology at Hospital Sant Joan de Deu, Barcelona, Spain, explained: “The main treatment for BSGs is radiotherapy. Surgery is not really an option because of the way the tumour is situated in life-threatening anatomical structures situated in the brain stem. However, for children the long-term adverse consequences of radiotherapy have meant that doctors have looked to clinical trials to see if chemotherapy could be substituted for radiotherapy. However, most of these trials have failed; at present, many centres use radiation therapy for high-grade gliomas and diffuse intrinsic pontine tumours, the deadliest of all BSGs. For low-grade gliomas in children few combination regimens have shown significant changes in the long-term natural history of this disease: vincristine and carboplatin is the current protocol and was pioneered by the Duke’s University group in the USA. The Italians have tested cisplatin and VP-16 with very good results for low-grade gliomas.”
BSGs are rare, but are amongst the commonest cancers to occur in children aged between about six and ten years old. The cause is unknown and the survival rates are poor: high-grade BSGs (diffuse and non-diffuse intrinsic tumours) are uniformly fatal, while children with low-grade gliomas have a more prolonged survival.
Dr Mora and his team enrolled six children out of 22 with BSGs in their trial. Four children had high-grade gliomas (two diffuse and two non-diffuse) and two had low-grade, mid-brain tumours. Irinotecan and cisplatin was given once a week for four weeks for a total of four cycles. Children with the high-grade tumours were also given anti-angiogenic therapy (bevacizumab) and radiotherapy.
Dr Mora said: “All patients had complete and rapid clinical responses to the I/C regimen. Remarkably, the I/C regimen achieved a reduction in tumour size greater than 20 percent in all the children at the end of the therapy, including those with the worst BSGs, the intrinsic diffuse BSGs. No chemotherapy has ever achieved this grade of early response in high-grade BSGs.”
Between nine and twelve months after the therapy, three of the high-grade tumours started to progress again.
Dr Mora said: “This early response is promising but the high-grade patients eventually progress regardless of the maintenance therapy we have given them. We need to rethink these results and find out how to consolidate better these initial responses.”
The other 16 children with BSGs had received different treatments by the start of the trial and they made up the historical cohort. After an average of 25 months, ten of them (65 percent) were still alive. These results cannot be compared directly with the results from the clinical trial but give an indication of how difficult it is to prolong survival for this disease.
Second cause of hidden hearing loss identified
20.02.2017 | Michigan Medicine - University of Michigan
Prospect for more effective treatment of nerve pain
20.02.2017 | Universität Zürich
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
21.02.2017 | Earth Sciences
21.02.2017 | Medical Engineering
21.02.2017 | Trade Fair News